Pages that link to "Q36655269"

The following pages link to Rimonabant: endocannabinoid inhibition for the metabolic syndrome (Q36655269):

Displaying 14 items.

• Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. (Q30366778) (← links)
• Sex differences in the cannabinoid modulation of appetite, body temperature and neurotransmission at POMC synapses (Q33667914) (← links)
• A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates (Q36368922) (← links)
• The role of endocannabinoid system blockade in the treatment of the metabolic syndrome (Q36773310) (← links)
• The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes (Q37000746) (← links)
• Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment (Q37149405) (← links)
• Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). (Q37226537) (← links)
• Cannabinoid-induced hyperphagia: correlation with inhibition of proopiomelanocortin neurons? (Q37287784) (← links)
• Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity (Q37483205) (← links)
• Diagnosis and treatment of severe hypertriglyceridemia (Q37998115) (← links)
• CB1 receptor antagonists: new discoveries leading to new perspectives (Q37998561) (← links)
• Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists (Q41371769) (← links)
• Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome (Q43052194) (← links)
• Acutely reduced locomotor activity is a major contributor to Western diet-induced obesity in mice (Q46888836) (← links)